Celine Biotechnologies
Celine Biotechnologies is a US biotech company building a precision AI platform on human-based data to discover biomarkers and advance immune rejuvenation medicine for early detection of cancer, inflammation, and neurodegenerative disease, targeting pharmaceutical, biotech, and oncology-center customers.
- Company typePrivate
- Founded2021
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Celine Biotechnologies does
Celine Biotechnologies (operating as Celine Bio) is a US-based, privately held biotechnology company founded in 2021 that develops a precision AI platform powered by human-based data to discover novel biomarkers and enable immune rejuvenation medicine. The company's stated technical focus is early detection of complex age-related diseases, specifically cancer and solid tumors, inflammation and immune dysregulation, and neurodegenerative disease. The platform architecture is described as scalable and data-driven, processing human-based biomarker data to surface novel diagnostic and therapeutic targets, with the central thesis being that restoring immune function can extend healthspan.
The underlying technology consists of three proprietary feature layers: an AI-driven biomarker discovery engine (novel method architecture), an immune rejuvenation medicine module (domain specialization), and an early detection capability positioned on accuracy and precision. A single unified product, the "Celine Bio Platform," is offered. No patents, peer-reviewed publications, named models, or disclosed dataset scale appear in the source material, so the technical maturity is verifiable only at the positioning level. The company does not expose an API, SDK, or downloadable application; all distribution is enterprise and in-person.
Commercially, the company remains pre-revenue with no publicly disclosed pricing and no named customers. Its indicated revenue mechanics are platform licensing to pharmaceutical companies for biomarker and companion-diagnostics development, and precision medicine solutions (subscription/recurring) for cancer centers and biotech firms addressing patient stratification. The go-to-market is event-driven and CEO-led, anchored on participation in pharma accelerator and validation programs (Merck Digital Sciences Studio, J&J Innovation Lab, Novo Nordisk Bio Innovation Hub, TMC Innovation Factory, Pear VC PFC, BioTools Innovator) and on visibility at industry venues such as the Galien Forum and the Memorial Sloan Kettering Life Sciences Innovation Summit. Capital support is disclosed from Pear VC, Northpond Ventures, Microsoft for Startups, Plug and Play, and NVIDIA, with no funding-round amounts or ownership terms available.
Celine Biotechnologies firmographics
Firmographics- Name
- Celine Biotechnologies
- Legal name
- Celine Biotechnologies
- Website
- https://celinebio.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Celine Biotechnologies is a US biotech company building a precision AI platform on human-based data to discover biomarkers and advance immune rejuvenation medicine for early detection of cancer, inflammation, and neurodegenerative disease, targeting pharmaceutical, biotech, and oncology-center customers.
- Ownership category
- akta.pro rank
Celine Biotechnologies industry classification
Industry- Product category
- Precision Medicine AI / Biomarker Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where Celine Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
Celine Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Biomarker Discovery Platform Licensing: The company develops an AI-powered platform for biomarker discovery and immune rejuvenation medicine that could be licensed to pharmaceutical and biotechnology companies for drug development and companion diagnostics
- Precision Medicine Solutions: Data-driven precision care solutions targeting complex age-related diseases including cancer, inflammation, and neurodegenerative conditions
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Celine Biotechnologies product offering
Product offeringCore offering
Celine Biotechnologies develops the Celine Bio Platform, a scalable precision AI platform powered by human-based biomarker data that unlocks novel biomarkers and supports immune rejuvenation medicine. The platform is used to enable early detection of complex age-related diseases — including cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative conditions — and is positioned for biomarker discovery, companion diagnostics, and data-driven precision care for pharmaceutical, biotechnology, and clinical customers.
Product overview
Celine Biotechnologies offers a single unified platform focused on Precision AI for early detection and immune rejuvenation. The platform is data-driven and scalable, leveraging human-based biomarker data to restore health and extend healthspan. The company addresses complex age-related diseases including cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- Celine Bio Platform A scalable precision AI platform powered by human-based biomarker data that unlocks novel biomarkers and enables immune rejuvenation medicine. Used for biomarker discovery, companion diagnostics, and early detection of cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative diseases. Targeted at pharmaceutical companies, biotechnology firms, and leading cancer centers.
Companies that use Celine Biotechnologies
Customer profileSegments3 records
Ideal customer profiles3 records
Celine Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Celine Biotechnologies partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, flagship and minor.
- Johnson & Johnson InnovationcoreCelineBio was accepted to Johnson & Johnson Innovation Lab and received Health Equity Hero recognition. CEO was invited by Johnson & Johnson to moderate Women In Bio-San Francisco Bay Area event. Company was also selected as finalist for Johnson & Johnson Innovation and CLS QuickPitch Poster session.
- Texas Medical Center (TMC)coreCelineBio was accepted to and successfully graduated from TMC Innovation Factory program for Cancer-Fighting Cohort of Innovators. TMC is the largest medical center in the world and home to the No.1 hospital for cancer care, MD Anderson Cancer Center.
- Merck Digital Sciences StudioflagshipSelected as inaugural member of Merck Digital Sciences Studio - only 12 companies accepted out of over 200+ applicants. This represents a significant validation of the company's technology platform.
- Plug and PlayminorListed among supporters and innovation ecosystem partners of CelineBio.
- Harvard Innovation LabminorListed among supporters of CelineBio, indicating academic institution partnership.
- MIT Innovation CenterminorListed among supporters of CelineBio, indicating academic institution partnership.
- Novo Nordisk Bio Innovation HubminorSelected as finalist by Novo Nordisk's Bio Innovation Hub, indicating partnership interest from Novo Nordisk.
- Memorial Sloan Kettering Cancer CentercoreInvited to present at MSKCC Life Sciences Innovation Summit, indicating recognition and potential partnership opportunity with a leading cancer center.
- BioLabsminorAccepted to present innovation solution at BioLabs Investor Day.
- BioTools InnovatorminorSelected to showcase innovative tech-bio platform during BioTools Innovator 2024 Road Tour in San Diego.
Scale indicators2 records
Recent moves6 records
Expansion highlights6 records
Celine Biotechnologies competitors and assessment
Company assessmentEmerging players
- Notable Labs: Notable Labs uses AI-driven biomarker testing to match cancer patients to therapies. Comparable to CelineBio on the AI/biomarker/cancer-therapeutic-selection thesis.
- PathAI: PathAI applies AI to pathology data for biomarker and diagnostic discovery. Comparable to CelineBio on the AI/biomarker intersection, with a pathology-specific focus.
Direct peers
- Absci: Absci is an AI-enabled biologic drug discovery platform using generative AI and wet-lab validation. Comparable to CelineBio on the AI/biologic-discovery intersection.
- Lantern Pharma: Lantern Pharma uses AI to identify biomarker signatures and match oncology therapies to patients. Directly comparable to CelineBio's AI/biomarker oncology focus.
- Freenome: Freenome applies AI to multiomics blood-based data for early cancer detection. Directly comparable to CelineBio's early-detection biomarker platform focus in oncology.
- Owkin: Owkin uses AI on real-world patient data to discover biomarkers and develop diagnostic and therapeutic solutions for cancer and other diseases. Closely overlaps with CelineBio's biomarker and precision-medicine positioning.
- Recursion Pharmaceuticals: Recursion uses AI and high-throughput biology for drug discovery across multiple disease areas. Comparable to CelineBio in applying AI to biological data to accelerate therapeutic and biomarker discovery.
- Insitro: Insitro is a machine-learning-driven drug discovery company combining human-based data with AI to discover therapeutics. Highly comparable to CelineBio's AI/human-data biomarker platform approach.
Broad incumbents
- Tempus Labs: Tempus is a large precision-medicine AI/data company with broad oncology and biomarker offerings. Overlaps with CelineBio's data-driven precision-care approach but at much greater scale and breadth.
- Schrödinger Inc. Schrödinger is a computational drug discovery platform combining physics-based simulation with AI. Comparable to CelineBio on AI-driven molecular discovery, with broader portfolio scope.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Celine Biotechnologies social profiles
Digital presenceCeline Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Celine Biotechnologies leadership team
Management profileNumber of profiles
Profiles1 record
Celine Biotechnologies funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Celine Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Celine Biotechnologies
What does Celine Biotechnologies do?
Celine Biotechnologies develops the Celine Bio Platform, a scalable precision AI platform powered by human-based biomarker data that unlocks novel biomarkers and supports immune rejuvenation medicine. The platform is used to enable early detection of complex age-related diseases — including cancer, solid tumors, inflammation, immune dysregulation, and neurodegenerative conditions — and is positioned for biomarker discovery, companion diagnostics, and data-driven precision care for pharmaceutical, biotechnology, and clinical customers.
Is Celine Biotechnologies a public or private company?
Celine Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was Celine Biotechnologies founded?
Celine Biotechnologies was founded in 2021. It employs 1 to 10 people.
Where is Celine Biotechnologies based?
Celine Biotechnologies is headquartered in Boston, United States, in the North America region.
How does Celine Biotechnologies make money?
Two revenue lines are on record. Biomarker Discovery Platform Licensing is the primary driver. The others are precision Medicine Solutions.
Who are Celine Biotechnologies's main competitors?
Emerging players on record are Notable Labs and PathAI. Direct peers are Absci, Lantern Pharma, Freenome, Owkin, Recursion Pharmaceuticals and Insitro. Broad incumbents are Tempus Labs and Schrödinger Inc..
Does Celine Biotechnologies have an API?
No public API is recorded for Celine Biotechnologies.
What industry is Celine Biotechnologies in?
Celine Biotechnologies's product category is Precision Medicine AI / Biomarker Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2835.